Last reviewed · How we verify
SPM 962
SPM 962 is a selective, high-affinity, and orally bioavailable small molecule inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1).
SPM 962 is a selective, high-affinity, and orally bioavailable small molecule inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1). Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | SPM 962 |
|---|---|
| Also known as | rotigotine |
| Sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Drug class | S1P receptor modulator |
| Target | S1PR1 |
| Modality | Small molecule |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 3 |
Mechanism of action
By selectively inhibiting S1PR1, SPM 962 is expected to reduce the number of circulating lymphocytes, thereby reducing inflammation and potentially treating autoimmune diseases. This mechanism of action is distinct from other S1P receptor modulators, which often have a broader range of activity and may have different safety profiles.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Nausea
- Headache
- Diarrhea
- Fatigue
Key clinical trials
- Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa (PHASE3)
- A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease (PHASE3)
- Study of SPM 962 in Patients With Restless Legs Syndrome (RLS) (PHASE3)
- A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients (PHASE3)
- A Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject (PHASE1)
- A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients (PHASE2)
- A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome (PHASE2)
- A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPM 962 CI brief — competitive landscape report
- SPM 962 updates RSS · CI watch RSS
- Otsuka Pharmaceutical Co., Ltd. portfolio CI